Last reviewed · How we verify
NCT06729333: SChiROP
A Multicenter and Prospective Study of Screening Retinopathy of Prematurity in China
trial in Premature Birth of Newborn in 5,000 participants. Not yet recruiting.
14 December 2025
Quick facts
| Lead sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 15 December 2024 |
| Primary completion | 14 December 2025 |
| Estimated completion | 14 June 2026 |
| Sites | 1 location across China |
Conditions studied
- Premature Birth of Newborn — all drugs for Premature Birth of Newborn →
- Retinopathy of Prematurity (ROP) — all drugs for Retinopathy of Prematurity (ROP) →
- Low Birthweight Infant — all drugs for Low Birthweight Infant →
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Who can join
Eligibility, any sex, with Premature Birth of Newborn or Retinopathy of Prematurity (ROP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to explore the current incidence rate of retinopathy of prematurity (ROP) in China and to explore more appropriate screening criteria for ROP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06729333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Premature Birth of Newborn
Currently open trials in the same condition.
- NCT02452580 — The Norwegian Family Centered Care Study · active not recruiting
Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
- NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
- NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
- NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
- NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06729333 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06729333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing